Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.33 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | CDK1 | P06493 | 3/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 3/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | BCL3 | P20749 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.30 |
| ▸ | HTR1F | P30939 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578221 | 0.90 | BRAF (0.33) | ABL1BRAFCCNA2CDK2CDK1 | |
| SCHEMBL5578360 | 0.87 | BRAF (0.34) | BRAF | |
| SCHEMBL5578179 | 0.85 | BRAF (0.34) | BRAF | |
| SCHEMBL8299912 | 0.79 | CDK2 (0.34) | ABL1BRAFCCNA2CDK2CDK1 | |
| SCHEMBL5578320 | 0.79 | ABL1 (0.37) | ABL1BRAFCCNA2CDK2CDK1 | |
| SCHEMBL5578323 | 0.78 | MAPK14 (0.37) | ABL1CCNA2CDK2CDK1CCNB1 | |
| SCHEMBL5578213 | 0.78 | CCNA2 (0.34) | ABL1BRAFCCNA2CDK2CDK1 | |
| SCHEMBL12446246 | 0.77 | CDK2 (0.34) | ABL1BRAFCCNA2CDK2CDK1 | |
| SCHEMBL14511688 | 0.77 | BRAF (0.32) | ABL1BRAFCCNA2CDK2CDK1 | |
| SCHEMBL3589567 | 0.77 | CDK2 (0.40) | ABL1CCNA2CDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1648449-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005002576-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | ABL1 511/4885BRAF 643/4885CCNA2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.